Axogen (AXGN)

Axogen’s portfolio is built around biologic and device-based solutions designed to support nerve reconstruction. Its best-known product is Avance Nerve Graft, a processed human nerve allograft used as an alternative to harvesting a patient’s own nerve tissue. The company also markets Axoguard Nerve Connector and Axoguard Nerve Protector, which help guide or protect nerve repairs, as well as Axoguard Nerve Cap and Avive Soft Tissue Membrane for related surgical applications. Axotouch, a two-point discriminator, is used by clinicians to assess sensory recovery by measuring skin innervation density.

The company sells primarily to surgeons and health care providers, with products used in procedures involving traumatic injuries, oral and maxillofacial surgery, hand surgery, and other reconstructive specialties. Axogen’s commercial reach includes the United States and selected international markets, including Canada and several European countries.

What distinguishes Axogen is its concentration on a specialized segment of regenerative medicine where treatment options can be limited and clinical outcomes are highly dependent on surgical technique and appropriate repair materials. Investors typically watch procedure adoption, reimbursement, surgeon education, clinical evidence, manufacturing capacity, and regulatory developments when evaluating AXGN.